Everand Logo

Welcome to Everand!

  • STAT

    Opinion: We need smart coronavirus testing, not just more testing

    "Testing is not a panacea" but intelligent application of #coronavirus testing will provide vital public health information needed to effectively fight this pandemic.
    by Farzad Mostashari and Ezekiel J. Emanuel Mar 24, 2020 5 minutes
    A medical personnel member takes samples from a woman at a drive-through coronavirus testing lab set up by a local community center in West Palm Beach, Fla.

    Despite three weeks of assurances, most Americans who have symptoms of Covid-19 still can’t get tested for SARS-CoV-2, the coronavirus that causes the disease. Last Friday, Sen. Brian Schatz (D-Hawaii) tweeted succinctly, “Hey where are the tests.”

    The hardest-hit states are rationing tests to health workers and those who have Covid-19 symptoms. The Trump administration, meanwhile, continuously reassures us that we are getting more and more testing out there.

    While increasing the number of tests is absolutely necessary, it is not sufficient. If we want to stop Covid-19, we must also focus on gathering other essential information as these tests are administered. There’s little value to getting a bunch of positive test results without being able to understand the clinical conditions of the individuals they came from, how they were exposed

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks